Previous 10 | Next 10 |
Otonomy (OTIC) has priced its public offering of ~6.3M common shares at $2.25/share and, pre-funded warrants to purchase up to ~7.1M shares at $2.249/pre-funded warrant.Expected gross are ~$30.1M.Underwriters' over-allotment is an additional 2.01M shares. Cowen and Piper Sandler are acting as...
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock at a price ...
Otonomy (OTIC) announces that it has commenced an underwritten public offering of shares.Expects to grant the underwriters a 30-day option to purchase up to an additional 15% of shares.Further financial details of the offering were not disclosed.Cowen and Piper Sandler are acting as joint boo...
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the 20 th Annual Needham Virtual Healthcare Conference. David A. Web...
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1...
Otonomy (OTIC) announces the initiation of a Phase 2 clinical trial of OTO-313 in patients with unilateral tinnitus, a common problem that negatively impacts millions of people by disrupting their ability to sleep, concentrate at work, and enjoy leisure activities.The randomized, do...
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpoint Patient enrollment criteria refined to enrich study population Top-line results expected in mid-2022 ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The major averages finished the week with sharp losses, despite a Friday rebound in the big tech stocks following an earlier selloff sparked ...
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in three upcoming virtual conferences: A fireside cha...
Gainers: ReTo Eco-Solutions (RETO) +93%.Celsion (CLSN) +62%.Rodgers Silicon Valley Acquisition (RSVA) +49%.Taoping (TAOP) +44%.RealNetworks (RNWK) +32%.Cooper Tire & Rubber (CTB) +30%.MICT (MICT) +26%.Conformis (CFMS) +26%.ATIF Holdings (ATIF) +25%.Vuzix (VUZI) +23%.Losers:...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...